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Mucus secretion is often uncontrolled in many airway inflammatory diseases of humans. Identifying the regulatory pathway(s) of
mucus gene expression, mucus overproduction, and hypersecretion is important to alleviate airway inflammation in these diseases.
However, the regulatory signaling pathway controlling mucus overproduction has not been fully identified yet. In this study, we
report that the ATP/P2Y
2
complex secretes many cytokines and chemokines to regulate airway inflammation, among which IL-
1 receptor antagonist (IL-1ra) downregulates MUC5AC gene expression via the inhibition of G𝛼q-induced Ca2+ signaling. IL-1ra
inhibited IL-1𝛼 protein expression and secretion, and vice versa. Interestingly, ATP/P2Y
2
-induced IL-1ra and IL-1𝛼 secretion were
both mediated by PLC𝛽3. A dominant-negative mutation in the PDZ-binding domain of PLC𝛽3 inhibited ATP/P2Y
2
-induced IL-
1ra and IL-1𝛼 secretion. IL-1𝛼 in the presence of the ATP/P2Y
2
complex activated the ERK1/2 pathway in a greater degree and
for a longer duration than the ATP/P2Y
2
complex itself, which was dramatically inhibited by IL-1ra. These findings suggest that
secreted IL-1ra exhibits a regulatory effect on ATP/P2Y
2
-inducedMUC5AC gene expression, through inhibition of IL-1𝛼 secretion,
to maintain the mucus homeostasis in the airway. Therefore, IL-1ra could be an excellent modality for regulating inflamed airway
microenvironments in respiratory diseases.
1. Introduction
Mucus overexpression and hypersecretion in the human
respiratory track are a critical characteristic of a number
of pulmonary diseases including rhinitis, sinusitis, asthma,
COPD, and cystic fibrosis [1]. A family of highly glycosylated
proteins, named mucins, has been identified as important
constituents of mucus. However, the physiological functions
of mucins have not been fully understood yet. In the
human body, several innate immune systems downregulate
mucin overexpression and hypersecretion, thus decrease
inflamed microenvironments, and maintain homeostasis.
Identification of the regulatory mechanisms which lead to
control mucin overexpression and hypersecretion in pul-
monary diseases is essential for developing new therapeutic
drugs. Since MUC5AC (for human; Muc5ac for nonhumans)
is one of the major mucins in human airway diseases, the
mechanisms regulatingMUC5AC gene expression have been
considered critical to identify strategies to prevent airway
mucus overproduction.
The IL-1 family of molecules consists of two agonists,
IL-1𝛼 and IL-1𝛽, and a specific receptor antagonist called
IL-1ra, which interact with two different receptors, IL-1R
type I (IL-1RI) and IL-1R type II (IL-1RII) [2, 3]. The IL-1
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family plays an important role in maintaining homeostasis
against microorganisms, air pollutants, exotoxins, and air-
borne particulate matters in the human respiratory track. It
also takes an important part in the innate immune system,
which further regulates functions of the adaptive immune
system [4].The balance between IL-1 and IL-1ra in the human
lung may affect the development of inflammatory diseases.
Voelkel et al. reported that treatment with IL-1ra reduced
pulmonary hypertension generated by monocrotaline in rats
[5], but IL-1𝛽, one of the earliest mediators secreted during
a proinflammatory response, is present at high levels in the
lungs of patients with chronic lung diseases [6]. However,
other secreted inflammatory mediators can also regulate
their intracellular expressions, thereby further modulating
cytokine-regulated MUC5AC overproduction.
The purinergic P2Y
2
receptor (P2Y
2
R) is highly expressed
in the apical membrane of the respiratory track [7–9]. Extra-
cellular nucleotides bound to the P2Y
2
R have been shown to
induce a number of physiological phenomena in a variety of
human cell types and tissues [10]. Recently, P2Y
2
R deficiency
was shown to attenuate IFN𝛾, IL-17, and TNF𝛼 secretion
in mice [11]. P2Y couples to the G-protein subtype, G𝛼q,
and the G𝛼q protein regulates Ca2+ influx upon stimulation
with ligands [12]. Next, elevated [Ca2+]i increases PLC𝛽3.
PLC𝛽 isotypes have a long C-terminal region (∼400 residues)
with relatively low homology among family members [13].
This C-terminal region (residues 903–1142 of PLC𝛽1) is
required for binding and stimulation by G𝛼q [14]. Moreover,
PLC𝛽 isotypes possess short consensus sequences known
as postsynaptic density- (PSD-) 95/disc large/ZO-1- (PDZ-)
binding motifs. The PDZ-binding motif is a well-known
short linear motif that interacts with other PDZ proteins
[15].The regulatorymechanism of PLC𝛽3-mediated cytokine
secretion to controlMUC5AC gene expression and the signal
molecules involved, especially those involved in downstream
signaling of PLC𝛽3, has not yet been demonstrated in the
human airway epithelium.
Here, we report that ATP induces IL-1ra overexpression
and secretion via the P2Y
2
receptor in human airway epithe-
lial cells. IL-1ra secretion was associated with the P2Y
2
-G𝛼q-
[Ca2+]i-PLC𝛽3-ERK1/2 pathway, sequentially. Secreted IL-
1ra inhibits ATP/P2Y
2
-induced MUC5AC gene expression,
but IL-1𝛼 significantly increases the expression ofMUC5AC.
The results of the present study reveal a novel mechanism
for intra- and intercellular signaling pathways that control
airway inflammation, thus, providing an opportunity for
the development of novel therapeutic modalities to treat
respiratory diseases.
2. Materials and Methods
2.1. Materials. ATP and Apyrase were purchased from Sigma
Aldrich (St. Louis,MO).The IL-1ra and IL-1𝛼ELISA kits were
purchased form R&D Systems (Minneapolis, MN). siRNA
targeting P2Y
2
was synthesized by Bioneer (Daejeon, Korea):
P2Y
2
, GAGGAAGGUGGCUUACCAA (dTdT); and negative
control CCUACGCCACCAAUUUCGU (dTdT). All PLC𝛽3
isotypes were kindly provided by Dr. Pann-Ghill Suh (School
of Life Sciences, Ulsan National Institute of Science and
Technology, Ulsan, Korea).
2.2. Cytokine Assay. The cytokine assay was performed using
a Human Cytokine Array Panel A kit (R&D Systems) accord-
ing to the manufacturer’s instructions. Briefly, cells were
plated in 6-well plates one day prior to transfection with
either P2Y
2
or siRNA-P2Y
2
using FuGENE 6 (Roche; Indi-
anapolis, IN). Twenty-four hours after transfection, serum-
starved cells were treated with ATP for 4 hours. After
treatment, the supernatant was assayed according to the kit
instructions.
2.3. RT-PCR. Real-time PCR was performed using a BioRad
iQ iCycler Detection System (BioRad Laboratories; Hercules,
CA) with iQ SYBR Green Supermix. Reactions were per-
formed in a total volume of 20 𝜇L including 10 𝜇L 2x SYBR
Green PCR Master Mix, 300 nM of each primer, and 1𝜇L
of previously reverse-transcribed cDNA template. The fol-
lowing primers were used: MUC5AC, forward 5󸀠-CAGCCA-
CGTCCCCTTCAATA-3󸀠 and reverse 5󸀠-ACCGCATTT-
GGGCATCC-3󸀠; 𝛽
2
-microglobulin used as a reference for
normalization, forward 5󸀠-CGCTCCGTGGCCTTAGC-3󸀠
and reverse 5󸀠-GAGTACGCTGGATAGCCTCCA-3󸀠. Param-
eters were 95∘C for 10m, followed by 40 cycles of 95∘C for 15 s,
60∘C for 30 s, and 72∘C for 30 s. All reactions were performed
in triplicate. Relative quantity of MUC5AC mRNA was
obtained using a comparative cycle threshold method and
was normalized using 𝛽
2
-microglobulin as an endogenous
control.
2.4. Western Blot Analysis. NCI-H292 cells were grown to
confluence in 6-well plates. After treatment with ATP, cells
were lysed with 2x lysis buffer (250mM Tris-Cl (pH 6.5),
2% SDS, 4% 𝛽-mercaptoethanol, 0.02% bromphenol blue,
and 10% glycerol). Equal amounts of whole cell lysates
were resolved by 10–15% SDS-PAGE and transferred to
polyvinylidene difluoride membranes (Millipore, Bedford,
MA). Membranes were blocked with 5% skim milk in Tris-
buffered saline (50mM Tris-Cl (pH 7.5), 150mM NaCl) for
2 h at room temperature. Blots were then incubated overnight
with primary antibodies in TTBS (0.5% Tween 20 in Tris-
buffered saline). After washing with TTBS, blots were further
incubated for 45min at room temperature with anti-rabbit
or anti-mouse antibody (Cell Signaling; Danvers, MA) in
TTBS and visualized using the ECL system (GE Healthcare;
Uppsala, Sweden).
2.5. Measurement of Intracellular Ca2+ Concentration
([Ca2+]i). NCI-H292 cells were seeded on cover glasses in
35-mm dishes (5 × 104 cells). After 24 h, cells were transfected
with P2Y
2
-expressing construct. The cells expressing P2Y
2
in physiological salt solution [140mM NaCl, 5mM KCl,
1mM MgCl
2
, 1 mM CaCl
2
, 10mM HEPES, 10mM glucose,
and 310mOsm, (pH 7.4)] were incubated with 5 𝜇M Fura-
2/AM (TEFLabs Inc., Austin, TX) and 0.05% pluronic
F-127 for 60min at room temperature. Fura-2 fluorescence
was measured at the appropriate excitation wavelengths
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(340/380 nm), and emission at 510 nm wavelengths (ratio =
F340/F380) using a Molecular Devices (Downingtown, PA)
imaging system. The emitted fluorescence was monitored
with a charge-coupled device camera (Photometrics, Tucson,
AZ) attached to an invertedmicroscope. Fluorescence images
were obtained at 2 sec intervals. All data were analyzed using
MetaFlour software (Molecular Devices).
2.6. Statistical Analysis. Data are presented as the mean ±
S.D. of at least three independent experiments.Where appro-
priate, statistical differences were assessed by the Wilcoxon
Mann-Whitney test. 𝑝 values less than 0.05 were considered
statistically significant.
3. Results
3.1. ATP Secretes IL-1ra Extracellularly via the G𝛼q-Coupled
P2Y
2
Receptor in NCI-H292 Cells. In our previous study
[12], ATP was shown to induce MUC5AC gene expres-
sion via the P2Y
2
receptor and the MAPK pathway in
NCI-H292 (mucoepidermoid pulmonary carcinoma) cells.
To determine whether ATP treatment induces or inhibits
secretion of cytokines that may regulate the respiratory
microenvironment to maintain homeostasis, we performed
the cytokine array with cell culture medium after treatment
of NCI-H292 cells with ATP for 4 hours (Figure 1(a)). The
secretion of IL-1 receptor antagonist (IL-1ra) was increased
in cells overexpressing P2Y
2
, but not in cells transfected
with P2Y
2
-specific siRNA (Figure 1(a)). To examine whether
P2Y
2
is essential for IL-1ra secretion and overproduction,
we performedWestern blot analysis (Figure 1(b)) and IL-1ra-
specific ELISA (Figure 1(c)) in the presence or absence of
transfectionwith the constructs forwild-type P2Y
2
or siRNA-
P2Y
2
expression. Treatment with ATP alone for four hours
did not induce either IL-1ra secretion or overproduction;
however, ATP did induce IL-1ra secretion and overpro-
duction in cells overexpressing P2Y
2
. Conversely, siRNA-
mediated knockdown of P2Y
2
dramatically decreased ATP-
mediated induction of IL-1ra secretion and overproduction.
After showing that IL-1ra secretion was accelerated early by
the inflammatory response, we examined whether ATP/P2Y
2
signaling could induce IL-1ra overproduction. We previ-
ously showed that IL-1𝛼 secretion and overproduction were
upregulated by the ATP/P2Y
2
signaling complex in airway
epithelium [16]. Extracellular secretion of IL-1ra reached its
maximum level after 4 hours of treatment with ATP/P2Y
2
and decreased thereafter (Figure 1(d)). Next, to investigate
whether extracellular ATP secreted by exogenous ATP-
induced P2Y
2
activation is required for this phenomenon,
cells were incubated with Apyrase, an ATPase/ADPase, in
order to block the action of secreted ATP, followed by incu-
bation with ATP𝛾S, which is not hydrolyzed by Apyrase. IL-
1ra secretion induced by ATP𝛾S treatment was decreased in
an Apyrase dose-dependent manner (Figure 1(e)), indicating
that the secreted ATP rather than the treated ATP is critical
for increased IL1-ra secretion. In addition, we also compared
the stimulatory activities of various nucleotides for IL-1ra
secretion. Only ATP or UTP could dramatically increase
the secretion of IL-1ra in cells expressing P2Y
2
(Figure 1(f)).
The effects of nucleotides on IL-1ra secretion were as follows:
ATP > UTP > GTP = ADP = UDP. These results suggest
that intracellular secretion of IL-1ra is stimulated by the
ATP/P2Y
2
complex, which plays an important immuno-
logical role to control inflammatory signaling in airway
cells. These results demonstrated that cells activated by
the ATP/P2Y
2
complex could promote secretion of ATP,
which may trigger signal transduction pathways in either
an autocrine or paracrine manner, resulting in subsequent
secretion of IL-1ra from the cells. ATP/P2Y
2
is appeared to
be essential for extracellular secretion and overproduction of
IL-1ra in airway epithelial cells.
3.2. IL-1ra Antagonizes IL-1𝛼 Secretion and Overproduction to
Inhibit IL-1𝛼-Induced MUC5AC Gene Expression. We previ-
ously showed thatMUC5AC gene expressionwas upregulated
by LPS-induced secretion of ATP [17]. In addition, IL-1𝛼
secretionwas alsomediated by ATP/P2Y
2
signaling to induce
MUC8 gene expression [16]. Thus, we hypothesized that IL-
1ra secreted by ATP/P2Y
2
might regulate IL-1𝛼 secretion and
overproduction to antagonize IL-1𝛼 function. Moreover, we
speculated that IL-1𝛼 secretion could alter IL-1ra secretion
and overproduction, reciprocally. First, we confirmed that
the P2Y
2
complex was essential for ATP-induced MUC5AC
gene expression in human airway epithelial NCI-H292
cells (Figure 2(a)) [12]. Second, P2Y
2
-transfected cells were
treated with either ATP only or ATP and IL-1ra (50 ng/mL)
for 4 hours. We found that IL-1ra treatment inhibited
ATP/P2Y
2
-induced IL-1𝛼 overproduction by Western blot
analysis (Figure 2(b), upper panel) and its secretion by ELISA
(Figure 2(b), lower panel). In the same way, IL-1𝛼 treatment
also inhibited IL-1ra secretion and overproduction, recipro-
cally (Figure 2(c)). Next, we investigated whether secreted
IL-1𝛼 or IL-1ra by ATP/P2Y
2
could increase MUC5AC gene
expression in airway epithelial cells. Interestingly, whereas
IL-1ra treatment dramatically decreasedATP/P2Y
2
-mediated
induction of MUC5AC gene expression, IL-1𝛼 treatment
slightly increased expression of MUC5AC (Figure 2(d)). To
examine the role of IL-1ra in IL-1𝛼 secretion by cells express-
ing P2Y
2
, we cotreated cells with both IL-1𝛼 (50 ng/mL) and
IL-1ra in a dose-dependent manner (0, 100, and 150 ng/mL)
as a competitive inhibitor, reciprocally. Because IL-1ra has
the same binding strength for the IL-1 receptor as IL-
1𝛼, the intrinsic agonist activity of IL-1𝛼 may abolish its
own function. High dosages (100 and 150 ng/mL) of IL-
1ra markedly reduced IL-1𝛼 (50 ng/mL)-induced MUC5AC
gene expression; however, IL-1𝛼 dosages (100 and 150 ng/mL)
dramatically increased IL-1ra (50 ng/mL)-reduced expression
(Figure 2(e)). These results indicate that IL-1ra secretion
antagonizes physiological phenomena induced by IL-1𝛼.
Therefore, IL-1ra secreted by the ATP/P2Y
2
complex can
regulate airway inflammation to decrease MUC5AC gene
expression in airway epithelial cells.
3.3. IL-1ra Abolishes G𝛼q-Mediated PLC𝛽3 Activation and
Ca2+ Secretion. To determine whether IL-1ra or IL-1𝛼 can
affect phospholipase C (PLC) 𝛽3 activation, we performed
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Figure 1: ATP induces IL-1ra secretion and overexpression through a P2Y
2
-dependent pathway inNCI-H292 cells. (a) A construct expressing
wild-type P2Y
2
or siRNA-P2Y
2
was transiently transfected into NCI-H292 cells. The cells were washed and serum-starved overnight. They
were subsequently treated with ATP for 4 hours and a cytokine assay was performed. (b) Cells were transfected with either a construct driving
the expression of wild-type P2Y
2
or P2Y
2
-specific siRNA. Cells were then treated with ATP for four hours and their supernatants collected.
The total cell lysates were analyzed byWestern blot analysis. Mock transfection was performed with parent pcDNA3 only. (c)The levels of IL-
1ra in the cell supernatants were measured by ELISA. ∗𝑝 < 0.05 compared with ATP only; ∗∗𝑝 < 0.05 compared with ATP/P2Y
2
-treated cells.
(d) Cells were transfected with pcDNA3.1::P2Y2 or pcDNA3.1 and were treated with ATP (10𝜇M) for the indicated times. The concentrations
of IL-1ra in the resultant supernatants were measured by ELISA. Values shown are the means ± SD of three technical replicates from a
single experiment. ∗𝑝 < 0.05 compared with the ATP only treatment each time. (e) After transfection with wild-type P2Y
2
, the cells were
subsequently treated with Apyrase for 4 hours prior to treatment with ATP𝛾S (10 𝜇M) for 4 hours. IL-1ra secretion was measured by ELISA.
Values shown represent themeans± SDs of three technical replicates from a single experiment. ∗𝑝 < 0.05 compared to the control, ∗∗𝑝 < 0.05
compared to ATP only, and ∗∗∗𝑝 < 0.05 compared to ATP/P2Y
2
-treated cells. (f) Cells transfected with either pcDNA3 or wild-type P2Y
2
were treated with nucleotides (10 𝜇M each) for 4 hours. IL-1ra secretion was measured by ELISA. Values shown represent the means ± SDs
of three technical replicates from a single experiment. ∗𝑝 < 0.05 compared with control. Data shown are representative of three independent
experiments.
Western blot analysis with a phospho-specific PLC𝛽3 anti-
body (Figure 3(a)). IL-1ra dramatically inhibited PLC𝛽3
phosphorylation, whereas IL-1𝛼 slightly increased phospho-
rylation of PLC𝛽3. PLC𝛽3 has short consensus sequences
known as postsynaptic density-95/discs large/ZO-1- (PDZ-)
bindingmotifs that consist of the amino acids X(S/T)X(V/L)-
COOH at the immediate C-terminus [12, 15]. The PDZ
domain of PLC𝛽3 is critical for binding to the four amino
acids at the C-terminus of target proteins [18–20]. To inves-
tigate whether the PDZ domain of the PLC𝛽3 C-terminus
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Figure 2: IL-1ra inhibits IL-1𝛼-induced MUC5AC gene expression via inhibiting IL-1𝛼 secretion and overproduction. (a) Cells were
transfected with either a construct driving the expression of wild-type P2Y
2
or siRNA specific for P2Y
2
. Cells were then treated with ATP
for 24 hours prior to the generation of total cell lysates, and then qRT-PCR forMUC5AC transcript was performed. ∗𝑝 < 0.05 compared to
the control, ∗∗𝑝 < 0.05 compared to ATP only, and ∗∗∗𝑝 < 0.05 compared to ATP/P2Y
2
-treated cells. (b) After transfection with wild-type
P2Y
2
or siRNA-P2Y
2
, the cells were subsequently treated with IL-1ra (50 ng/mL) for 4 hours prior to treatment with ATP for 4 hours. IL-1𝛼
production/secretion was measured by Western blot and ELISA, respectively, using the identical set of samples. Values shown represent the
means ± SDs of three technical replicates from a single experiment. Two additional experiments showed similar results. ∗𝑝 < 0.05 compared
to the control, ∗∗𝑝 < 0.05 compared to ATP only, and ∗∗∗𝑝 < 0.05 compared to ATP/P2Y
2
-treated cells. (c) Cells were transfected with either
a construct driving the expression of wild-type P2Y
2
or siRNA specific for P2Y
2
. The cells were subsequently treated with IL-1𝛼 (50 ng/mL)
for 4 hours prior to treatment with ATP for 4 hours. IL-1ra production/secretion was measured by Western blot and ELISA. Values shown
represent the means ± SDs of three technical replicates from a single experiment. ∗𝑝 < 0.05 compared to ATP only and ∗∗𝑝 < 0.05 compared
to ATP/P2Y
2
-treated cells. (d) After transfection with wild-type P2Y
2
, the cells were subsequently treated with either IL-1ra (50 ng/mL) or IL-
1𝛼 (50 ng/mL) for 4 hours prior to treatment with ATP for 24 hours. qRT-PCR forMUC5AC transcript was performed. ∗𝑝 < 0.05 compared
to the control, ∗∗𝑝 < 0.05 compared to ATP only, and ∗∗∗𝑝 < 0.05 compared to ATP/P2Y
2
-treated cells. (e) After transfection with wild-type
P2Y
2
, the cells were treated with both IL-1𝛼 (50 ng/mL) and IL-1ra (0, 100, 150 ng/mL) or both IL-1ra (50 ng/mL) and IL-1𝛼 (0, 100, 150 ng/mL)
for 4 hours prior to treatment with ATP for 24 hours. qRT-PCR forMUC5AC transcript was performed. ∗𝑝 < 0.05 compared to the control,
∗∗
𝑝 < 0.05 compared to ATP only, and ∗∗∗𝑝 < 0.05 compared to ATP/P2Y
2
-treated cells. Data shown are representative of three independent
experiments.
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plays a role in ATP/P2Y
2
-activated IL-1ra and IL-1𝛼 secre-
tion and overproduction, each of the last four amino acid
residues of PLC𝛽3 (1231NTQL1234-COOH) was mutated to
Ala [12].When treated with ATP for 4 hours, cells transfected
with the construct overexpressing wild-type PLC𝛽3 (NTQL)
showed an increase in IL-1𝛼 and IL-1ra secretion, whereas the
dominant-negative mutant, PLC𝛽3 NTQA (L1234A), signif-
icantly inhibited their secretion. In contrast, PLC𝛽3 ATQL
(N1231A), NAQL (T1232A), and NTAL (Q1233A) had no
inhibitory effect on IL-1𝛼 and IL-1ra secretion (Figure 3(b)).
These results indicate that the fourth amino acid (Leucine)
of the PDZ domain in PLC𝛽3 is critical for binding some
regulatory protein(s) to control IL-1ra and IL-1𝛼 secretion
and overexpression by the ATP/P2Y
2
signaling complex.
These results show that PLC𝛽3 may have a major physiolog-
ical function in the pathway mediating ATP/P2Y
2
-induced
IL-1ra and IL-1𝛼 secretion, thus, regulating MUC5AC gene
expression in NCI-H292 cells. P2Y
2
is a G𝛼q-coupled G-
protein receptor; therefore, we investigated whether IL-1ra
has an effect on P2Y
2
-induced Ca2+ influx after treatment
with ATP. IL-1ra significantly decreased [Ca2+]i, but IL-1𝛼
slightly increased [Ca2+]i (Figures 3(a) and 3(b)).
3.4. Downstream Signaling by PLC𝛽3 of the ERK1/2-CREB
Pathway Is Controlled by IL-1ra and IL-1𝛼. ERK1/2 signaling
is critical for ATP/P2Y
2
-induced MUC5AC gene expression
in airway epithelial cells [12]; therefore, we hypothesized
that IL-1ra or IL-1𝛼 may affect ERK1/2 MAPK activation.
Phosphorylation of ERK1/2 was increased by ATP treat-
ment for 5min but then decreased rapidly. ERK1/2 phos-
phorylation activated by IL-1𝛼 was prolonged compared
to phosphorylation by the ATP/P2Y
2
signaling pathway
(Figure 4(a)). However, IL-1ra treatment for 10min inhibited
ERK1/2 phosphorylation increased by ATP/P2Y
2
signaling.
Treatment with IL-1𝛼 or ATP for 10 and 15min, respec-
tively, had an additive effect on ERK1/2 phosphorylation,
which was dramatically inhibited by IL-1ra (Figure 4(b)).
Interestingly, treatment with both ATP and IL-1𝛼 resulted in
prolonged activity to maintain ERK1/2 activation, whereas
IL-1ra remarkably abolishedATP/P2Y
2
-induced ERK1/2 acti-
vation. These results suggest that IL-1𝛼 prolonged ERK1/2
activation, but IL-1ra had a negative effect on activation.
Next, to examine whether ERK1/2 MAPK is essential for IL-
1ra- or IL-1𝛼-modulated MUC5AC gene expression, U0126,
a MEK1/2 specific inhibitor, was evaluated (Figure 4(c)). As
expected, IL-1ra- and IL-1𝛼-mediated gene expression of
MUC5AC were downregulated by U0126. Thus, ERK1/2 may
be associated with IL-1ra- and IL-1𝛼-modulated MUC5AC
gene expression in human airway epithelial cells.
4. Discussion
MUC5AC, known as tracheobronchial mucin [21], is a major
mucin of lung mucus and is abundantly expressed during
acute and chronic lung diseases [22] and thereby greatly con-
tributes to disease morbidity and mortality [6]. As described
above, studies regarding MUC5AC have focused on the
signaling pathway for gene expression itself by different stim-
ulants, such as proinflammatory cytokines, LPS, endotoxins,
cigarette smoking, yellow dust, or airborne particulatematter
in several lung cell types. However, there are few reports on
regulatory pathways that controlMUC5AC secretion or over-
production. An understanding of the regulatory mechanisms
that control mucus hypersecretion in respiratory diseases is
essential for improving future therapies.
The important proinflammatory role of IL-1 in many
human diseases has been described over the past a decade.
The balance between IL-1 and IL-1ra has been extensively
studied in a variety of experimental animalmodels of diseases
including arthritis, inflammatory bowel disease (IBD), gran-
ulomatous and fibrotic lung disorders, infectious diseases,
and arterial diseases [4]. Extracellular ATP is known to
regulate a number of inter- and intracellular functions in
many cells and tissues [23]. ATP is extracellularly secreted in
response to LPS-induced airway inflammation in the respi-
ratory system [12]. In several studies, ATP/P2Y
2
signaling in
the airway is a critical sensor for airway exposure to airborne
allergens and secretes the IL-33 cytokine into the airway
lumen [24]. We hypothesized that ATP/P2Y
2
signaling may
function in maintaining homeostasis by abolishing inflamed
microenvironments in the airway or by creating amore severe
inflamed condition. Therefore, we tried to identify which
proteins or signaling molecules control these processes.
We speculated that IL-1ra and IL-1𝛼, which have opposite
regulatory roles, may also be important in human airway
epithelial cells. We found that IL-1ra or IL-1𝛼 has a negative
effect on production and secretion of each other, reciprocally.
This is consistent with the results of studies on leukocytes
showing that binding of IL-1𝛼 to IL-1RI results in induction
of bioactive IL-1𝛽 [25, 26] and sIL-1ra [27], whereas sIL-1ra
inhibits both the activity and synthesis of IL-1𝛼 and IL-1𝛽
in monocytes [28]. These results suggest that overexpression
of IL-1𝛼 and/or underproduction of IL-1ra predisposes one
to the development of disease; therefore, the therapeutic
administration of IL-1ra is efficacious in preventing tissue
damage [4].
P2Y
2
is a G𝛼q-coupled receptor; therefore, an increase
in the concentration of Ca2+ influx was not surprising result
of this study. However, it is notable that secreted IL-1ra or
IL-1𝛼 regulated the concentration of Ca2+ influx induced by
ATP/P2Y
2
(Figures 3(a) and 3(b)). More surprisingly, IL-
1ra inhibited PLC𝛽3 activation (Figure 3(a)). These results
suggest that Ca2+-PLC𝛽3 may be essential for IL-1ra- or IL-
1𝛼-regulated MUC5AC gene expression in airway epithelial
cells. Understanding the physiological features of the PDZ
domain in PLC𝛽3 will provide additional insight into the
molecular signalingmechanism that leads to protein complex
formation [12]. The PDZ domain is critical for signaling
because it depends heavily on the PDZ-binding partner
protein(s) to modulate positively/negatively its own signal
transduction pathway. Our previous study reported that the
PDZ domain in PLC𝛽3 is associated with ATP-induced
MUC5AC gene expression [12]. In the present study, we
found that the binding activity of the PDZ domain, and
consequently the function of PLC𝛽3, is determined by the
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Figure 3: Effect of PLC𝛽3 activation on IL-1ra and IL-1𝛼 secretion. (a) After transfection with wild-type P2Y
2
, the cells were subsequently
treated with IL-1ra or IL-1𝛼 for 4 hours prior to treatment with ATP for 5min. PLC𝛽3 activation was measured byWestern blot. Tubulin was
used as a loading control. (b) Cells were transiently transfected with both wild-type P2Y
2
and wild-type (1231NTQL1234), dominant-negative
PLC𝛽3ATQL (N1231A), NAQL (T1232A), NTAL (Q1233A), orNTQA (L1234A) construct. Each of the individual residues of the PDZ-binding
motif (NTQL) of PLC𝛽3 was mutated to Ala, respectively. Cells were serum-starved overnight and then treated with ATP for 4 hours, after
which supernatants were harvested for ELISA. For IL-1𝛼 ELISA (left panel), ∗𝑝 < 0.05 compared to the control, ∗∗𝑝 < 0.05 compared to
ATP only, ∗∗∗𝑝 < 0.05 compared to ATP/P2Y
2
-treated cells, and ∗∗∗∗𝑝 < 0.05 compared to ATP/P2Y
2
/wild-type PLC𝛽3-treated cells. For
IL-1ra ELISA (right panel), ∗𝑝 < 0.05 compared to ATP only, ∗∗𝑝 < 0.05 compared to ATP/P2Y
2
-treated cells, and ∗∗∗𝑝 < 0.05 compared
to ATP/P2Y
2
/wild-type PLC𝛽3-treated cells. Data shown are representative of three independent experiments. (c) After transfection with
wild-type P2Y
2
, the cells were treated with ATP, IL-1𝛼, or IL-1ra. Ca2+ release was measured by adding increasing concentrations of Fura-2.
See in Section 2. (d) Normalized peak value of the results in Figure 4(a). ∗𝑝 < 0.05 compared to ATP-treated cells, ∗∗𝑝 < 0.05 compared to
ATP/P2Y
2
/IL-1𝛼-treated cells.
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Figure 4: IL-1ra decreases ATP/P2Y
2
-inducedMUC5AC gene expression by inhibiting ERK1/2 activation. After transfection with wild-type
P2Y
2
, the cells were treated with either IL-1ra or IL-1𝛼 for 4 hours prior to treatment with ATP for different times (a) or either 10 or 15min (b).
ERK1/2 phosphorylation was analyzed byWestern blot. Tubulin was used as a loading control. (c) After transfection with wild-type P2Y
2
, the
cells were treated with IL-1ra, IL-1𝛼, or U0126 (10 𝜇M) for 4 hours prior to treatment with ATP for 24 hours. qRT-PCR forMUC5AC transcript
was performed. ∗𝑝 < 0.05 compared to the control, ∗∗𝑝 < 0.05 compared to ATP only, and ∗∗∗𝑝 < 0.05 compared to ATP/P2Y
2
-treated cells.
Data shown are representative of three independent experiments. (d) A schematic diagram is presented to show the potential mechanisms
for secretion of IL-1ra and IL-1𝛼, and their physiological roles during inflammatory responses.
ability of L1234, leading to secretion of IL-1ra or IL-1𝛼,
which in turn controls MUC5AC gene expression in airway
epithelial cells. This is a noteworthy result which suggests
that the balance between IL-1ra and IL-1𝛼 can contribute to
an inflamed microenvironment in the airway. For the same
reason, PDZ-binding partner protein(s) that can be recruited
to increase inflammatory conditions ormaintain homeostasis
in the respiratory track should further be investigated.
The molecule mediating PLC𝛽3 signaling to control IL-
1𝛼- or IL-1ra-regulatedMUC5AC gene expression is yet to be
elucidated. In our previous studies, ERK1/2 MAPK was iden-
tified as a molecule involved in cytokine-inducedmucin gene
expression [12, 13, 29]. Since this protein is tightly regulated
by PLC𝛽3 in NHNE and NCI-H292 cells [12], its effect on
ATP-mediated cytokine signaling also needed to be clarified.
The activation of ERK1/2 by IL-1𝛼 was more prolonged than
that of ATP alone (Figures 4(a) and 4(b)), suggesting that
ERK1/2 may be essential for ATP/P2Y
2
-induced MUC5AC
gene expression.This is not surprising since ERK1/2 played an
important role as a protein kinase to increaseMUC5AC gene
expression by various cytokines in our system. ATP/P2Y
2
-
induced ERK1/2 phosphorylation was inhibited by IL-1ra,
resulting in downregulation of ATP/P2Y
2
-inducedMUC5AC
gene expression. Consequently, IL-1ra secretion was affected
by PLC𝛽3 activation; thus, the secretion of IL-1ra could
control MUC5AC gene expression by regulating ERK1/2
activity (Figure 4(c)).
Taken together, we suggest that the interaction between
ATP and the P2Y
2
receptor led to the secretion of various
cytokines regulating airway inflammation. Not only can ATP
induce inflammation, but also it can also amplify and transfer
inflammatory signals to nearby epithelial cells in the airway.
The G𝛼q-PLC𝛽3-Ca2+ pathway modulated IL-1ra and IL-1𝛼
secretion to maintain homeostasis. Therefore, the balance
between these cytokines up- or downregulated MUC5AC
gene expression. In this signaling pathway, the PDZ domain
in PLC𝛽3 may play a crucial role in the development
of inflammation in the airway. In addition, secreted IL-
1ra diminished IL-1𝛼 production/secretion and MUC5AC
gene expression (Figure 4(d)). Thus, the development of a
Mediators of Inflammation 9
protein or small molecule as a novel therapeutic drug to
inhibit ATP/P2Y
2
signaling could be useful to control airway
inflammation.
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